EPA

Redirected from "Eicosapentaenoic acid"

Eicosapentaenoic acid (EPA) is a long-chain marine omega-3 fatty acid, abbreviated EPA and chemically described as 20:5 n-3. It is incorporated into cell membranes and can be converted into signaling molecules that help regulate inflammatory and vascular processes. That biochemical role does not make EPA an anti-inflammatory drug or prove a training benefit at any dose.

Fish and seafood provide preformed EPA, as can fish, krill, and some microalgal oils. Humans also form EPA from the essential plant fatty acid ALA, but the conversion is limited and variable. EPA can in turn be elongated and converted toward DHA, again with limited efficiency. A food's ALA content, a capsule's EPA content, and the body's resulting tissue levels therefore describe related but different things.

Research findings must be matched to the actual product and outcome. High-dose purified or prescription EPA preparations have been studied for selected medical indications, while ordinary supplements often contain a mixture of EPA and DHA at much lower amounts. Results from one formulation or high-risk patient group cannot be assumed for fish consumption, a standard fish-oil capsule, or a healthy lifter. The NIH omega-3 fact sheet summarizes these distinctions and the mixed evidence across cardiovascular outcomes.

For strength training, studies do not establish an EPA amount that reliably improves hypertrophy, strength, soreness, or post-exercise recovery in otherwise well-nourished adults. A measured effect on a blood marker or signaling molecule is not equivalent to a noticeable training outcome. EPA should therefore be evaluated as a nutrient or a condition-specific intervention, not as a required workout supplement.

On a product label, use the EPA amount rather than the total milligrams of oil to identify what is present. Also consider oxidation protection, storage, source, allergens, and independent quality testing. High-dose use should be reviewed alongside medicines that affect clotting, and atrial fibrillation can also matter in susceptible populations. A prescribed formulation and dose should therefore remain under clinical supervision.

See also: